CA Patent

CA2893836A1 — A combination medicament comprising phenylephrine and paracetamol

Assigned to AFT Pharmaceuticals Ltd · Expires 2014-08-07 · 12y expired

What this patent protects

Use of phenylephrine hydrochloride (or a pharmaceutically acceptable alternative form of phenylephrine) and paracetamol in the production of a combination medicament for treating upper respiratory mucosal congestion, comprising combining such substances with excipients, character…

USPTO Abstract

Use of phenylephrine hydrochloride (or a pharmaceutically acceptable alternative form of phenylephrine) and paracetamol in the production of a combination medicament for treating upper respiratory mucosal congestion, comprising combining such substances with excipients, characterised in that the medicament has the phenylephrine hydrochloride (or the pharmaceutically acceptable alternative form of phenylephrine) and paracetamol in proportions suitable for, and the medicament is for, providing an adult with: a) 4 mg - 7.5 mg phenylephrine hydrochloride (or an equivalent amount of a pharmaceutically acceptable alternative form of phenylephrine), in combination with 950 mg - 1,000 mg paracetamol; or b) 5 mg - 7.5 mg phenylephrine hydrochloride (or an equivalent amount of a pharmaceutically acceptable alternative form of phenylephrine), in combination with 600 mg - 700 mg paracetamol; or c) 6 mg - 8 mg phenylephrine hydrochloride (or an equivalent amount of a pharmaceutically acceptable alternative form of phenylephrine), in combination with 500 mg - 550 mg paracetamol.

Drugs covered by this patent

Patent Metadata

Patent number
CA2893836A1
Jurisdiction
CA
Classification
Expires
2014-08-07
Drug substance claim
No
Drug product claim
No
Assignee
AFT Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.